ImmunityBio (IBRX) Expected to Announce Earnings on Tuesday

ImmunityBio (NASDAQ:IBRX) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect ImmunityBio to post earnings of ($0.26) per share and revenue of $9.51 million for the quarter.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $2.87 on Friday. The business’s 50-day moving average is $3.08 and its 200 day moving average is $3.66. ImmunityBio has a 1 year low of $2.28 and a 1 year high of $10.53. The firm has a market capitalization of $2.45 billion, a P/E ratio of -3.12 and a beta of 0.82.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research report on Thursday. BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of ImmunityBio in a report on Thursday. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ImmunityBio presently has a consensus rating of “Buy” and an average target price of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.